These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 25787923)

  • 1. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
    Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
    Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
    Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG
    J Clin Oncol; 2010 Feb; 28(5):780-7. PubMed ID: 20048182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors.
    Nokihara H; Yamamoto N; Yamada Y; Honda K; Asahina H; Tamura Y; Hozak RR; Gao L; Suzukawa K; Enatsu S; Tamura T
    Jpn J Clin Oncol; 2017 Apr; 47(4):298-305. PubMed ID: 28158463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
    Zhu AX; Finn RS; Mulcahy M; Gurtler J; Sun W; Schwartz JD; Dalal RP; Joshi A; Hozak RR; Xu Y; Ancukiewicz M; Jain RK; Nugent FW; Duda DG; Stuart K
    Clin Cancer Res; 2013 Dec; 19(23):6614-23. PubMed ID: 24088738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
    Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
    Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
    Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
    LoRusso PM; Krishnamurthi S; Youssoufian H; Hall N; Fox F; Dontabhaktuni A; Grebennik D; Remick S
    Invest New Drugs; 2014 Apr; 32(2):303-11. PubMed ID: 23903897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.
    Lee SJ; Lee SY; Lee WS; Yoo JS; Sun JM; Lee J; Park SH; Park JO; Ahn MJ; Lim HY; Kang WK; Park YS
    Invest New Drugs; 2017 Dec; 35(6):782-790. PubMed ID: 28391576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
    Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
    Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
    Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
    Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
    Niwakawa M; Yamaguchi R; Onozawa Y; Yasui H; Taku K; Naito T; Akinaga S; Boku N; Yamamoto N
    Cancer Sci; 2013 Aug; 104(8):1039-44. PubMed ID: 23679664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
    J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
    Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
    Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.
    Cao J; Ji D; Chen Z; Shen W; Wang J; Li B; Chi H; Long A; Gao L; Li J
    Oncologist; 2017 Jun; 22(6):638-e56. PubMed ID: 28465370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
    Ueda S; Satoh T; Gotoh M; Gao L; Doi T
    Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.
    Harding JJ; Zhu AX; Bauer TM; Choueiri TK; Drilon A; Voss MH; Fuchs CS; Abou-Alfa GK; Wijayawardana SR; Wang XA; Moser BA; Uruñuela A; Wacheck V; Bendell JC
    Clin Cancer Res; 2019 Sep; 25(17):5202-5211. PubMed ID: 31142504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
    Patnaik A; LoRusso PM; Messersmith WA; Papadopoulos KP; Gore L; Beeram M; Ramakrishnan V; Kim AH; Beyer JC; Mason Shih L; Darbonne WC; Xin Y; Yu R; Xiang H; Brachmann RK; Weekes CD
    Cancer Chemother Pharmacol; 2014 May; 73(5):951-60. PubMed ID: 24633809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.
    Masuda N; Iwata H; Aogi K; Xu Y; Ibrahim A; Gao L; Dalal R; Yoshikawa R; Sasaki Y
    Jpn J Clin Oncol; 2016 Dec; 46(12):1088-1094. PubMed ID: 27608646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.